APAC DNA Sequencing Market

APAC DNA Sequencing Market Size (2022 to 2027)

The size of the DNA sequencing market in the Asia-Pacific is estimated to be growing at a healthy CAGR of 18.45% between 2022 to 2027.

Factors such as increasing demand for animal and plant breeders expanded research and development activities, and the acceptance of advanced technology is pushing the Asia-Pacific DNA Sequencing market. Furthermore, the proliferation of cancer and the expansion of biopsy applications are anticipated to accelerate the market. Newmarket players have been attracted to the APAC region's DNA sequencing market, fueling the region's market growth. The growing cancer occurrence has a significant impact on the DNA sequencing market. Besides that, the increasing use of genome mapping systems in Asian countries fuels market growth.

Furthermore, favorable government incentives, investment, and funding for infrastructure improvements facilities would boost the market growth. DNA sequencing is a highly accurate and high-throughput technology, and it has created a new form of genomic research. DNA sequencing is used in various applications, including biomarkers, personalized medicine, oncology research, and forensics. Advances in molecular biology have improved the sequencing protocols as the. The market has grown significantly in recent years due to several industry leaders introducing innovative NGS technologies. The cloud-based hub streamlines genomics data storage, maintenance, and analysis. In the same way, initiatives and innovations in emerging markets are expected to stimulate market growth. Cost-effectiveness and current conversion parameters to generate efficient outcomes in genome medicines are likely to impact market growth.

The significant concerns such as accuracy and standardization and ethical and legal limitations associated with DNA sequencing are expected to diminish the market growth. 

Impact of COVID-19 on the APAC DNA sequencing market:

The spread of SARS-COV-2 showed a positive impact on the APAC regional DNA Sequencing market. COVID-19 began in Wuhan, China, in 2019. Many pharmaceutical and biopharmaceutical firms and key market players, and DNA Sequencing start-ups are emerging to contribute to regional research efforts in developing COVID-19 kits, vaccines, and therapies. Emerging economies like China and India have expanded their R&D efforts to produce vaccines and drugs to fight the novel coronavirus. Researchers from Fuyang City (China) were the first to sequence COVID-19 samples using the Oxford Nanopore Technologies (UK) MinION Mk1C. Nanopore products for rapid molecular diagnostics are being developed in China by increasing public health and CDC laboratories. The APAC regional market for DNA sequencing is expected to grow faster in the coming years.

This research report on the APAC DNA sequencing market has been segmented and sub-segmented into the following categories.

By Product & Services:

• Consumables
• Instruments
• Services

By Technology:

• Sanger Sequencing
• Next-Generation Sequencing
• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)
• Targeted Sequencing & Resequencing
• Third Generation DNA Sequencing  
• Single-Molecule Real-Time Sequencing (SMRT)
• Nanopore Sequencing

By Workflow:

• Pre-sequencing
• Sequencing
• Data Analysis

By Application:

• Oncology
• Reproductive Health
• Clinical Investigation
• Agri genomics & Forensics
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Consumer Genomics
• Others

By End-use:

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other Users

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the growing applications of DNA sequencing are strongly favoring the APAC market to lead the global DNA sequencing market during the forecast period. The APAC DNA sequencing market is expected to be driven by an increment in the amount of genome mapping programs in this region and increased research and development activities. China, India, and Japan are the region's significant contributors.

China led the APAC region's largest DNA sequencing market in the recent past. The presence of specialized healthcare services and continued technological advances in DNA sequencing by key market participants have resulted in a substantial market share. During the COVID-19 pandemic, Fuyang City (China) researchers were the first to sequence COVID-19 samples using the Oxford Nanopore Technologies (UK) MinION Mk1C, resulting in a positive impact on regional market growth.

The Indian DNA sequencing market is expected to expand at a rapid pace over the forecast period. Favorable government incentives and programs are anticipated to accelerate market growth. However, the government's increased investments in healthcare infrastructure stimulate the Indian DNA sequencing market. The availability of advanced clinical laboratories and successful market players is anticipated to push the market growth in the coming years. 

Japan is expected to contribute a moderate market share to the APAC regional market. The growing access to affordable genotyping assistance and the prevalence of generative alignment and personalized medicine are driving the market growth in this region.

KEY MARKET PLAYERS:

Some of the promising companies dominating the APAC DNA sequencing market analyzed in this report are Agilent Technologies, Inc., Abbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche Ltd, Illumina, Inc., LI-COR Biosciences, Inc., Pacific Biosciences of California, Inc., SIEMENS AG, PerkinElmer Inc., and Thermo Fisher Scientific, Inc.